A combination of cholecalciferol derivatives for the treatment of renal bone disease
作者： David Ladkani , Ben Zion Weiner , Zeev Mazor , Benjamin Shalita , Shmuel Edelstein
DOI:
关键词: Phosphate 、 Cholecalciferol 、 Renal bone disease 、 Renal osteodystrophy 、 Endocrinology 、 Calcium 、 Materials science 、 Internal medicine 、 Calcium concentration
摘要: A method and composition for an improved treatment of human renal osteodystrophy, comprising the administration 6-40 mcg/d (micrograms per day) 24,25(OH)₂D₃ in combination with amounts 1-alpha(OH)D₃ or 1,25(OH)₂D₃ DHT₂, which will maintain serum patients calcium concentration at 10-11 mg/dl (milligrams deciliter) phosphate 5.5-6.0 numerical multiplication product x not more than 60-65.
google.nl 参考文章(23)
Yasuo Nishii, Tadao Aoki, Hideo Miyakoshi, Yoshihei Hirasawa, Method for inhibiting the lowering of immunological function and agent therefor ,(1980)
Chikao Yoshikumi, Yasuhiko Kobayashi, Yuji Maeda, Takayoshi Fujii, Kenichi Saito, Hideyuki Yamato, Fumio Hirose, Tadaaki Kato, Method for inhibiting the formation of urinary calculus utilizing 24,25-(OH)2 -D3 ,(1987)
Heinrich K Schnoes, Michael F Holick, Hector F De Luca, 1,25-dihydroxycholecalciferol ,(1971)
Chikao Yoshikumi, Yasuhiko Kobayashi, Yuji Maeda, Takayoshi Fujii, Kenichi Saito, Hideyuki Yamato, Tadaaki Kato, Antiosteoporotic pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient ,(1984)
A. ORNOY, D. GOODWIN, D. NOFF, S. EDELSTEIN, 24, 25-dihydroxyvitamin D is a metabolite of vitamin D essential for bone formation. Nature. ,vol. 276, pp. 517- 519 ,(1978) , 10.1038/276517A0
Anthony B. Hodsman, Eugene G.C. Wong, Donald J. Sherrard, Arnold S. Brickman, David B.N. Lee, Frederick R. Singer, Anthony W. Norman, Jack W. Coburn, Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia The American Journal of Medicine. ,vol. 74, pp. 407- 414 ,(1983) , 10.1016/0002-9343(83)90959-2
A S Brickman, J W Coburn, G R Friedman, W H Okamura, S G Massry, A W Norman, Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. Journal of Clinical Investigation. ,vol. 57, pp. 1540- 1547 ,(1976) , 10.1172/JCI108424
M. R. Haussler, J. E. Zerwekh, R. H. Hesse, E. Rizzardo, M. M. Pechet, Biological Activity of 1α-Hydroxycholecalciferol, A Synthetic Analog of the Hormonal Form of Vitamin D3 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 70, pp. 2248- 2252 ,(1973) , 10.1073/PNAS.70.8.2248
J. Reeve, M. Tellez, J. R. Green, R. Hesp, U. Elsasser, R. Wootton, P. Hulme, D. Williams, J. A. Kanis, R. G. G. Russell, E. B. Mawer, P. J. Meunier, Long-Term Treatment of Osteoporosis with 24,25 Dihydroxycholecalciferol European Journal of Endocrinology. ,vol. 101, pp. 636- 640 ,(1982) , 10.1530/ACTA.0.1010636
A.M. Pierides, Pharmacology and Therapeutic Use of Vitamin D and its Analogues Drugs. ,vol. 21, pp. 241- 256 ,(1981) , 10.2165/00003495-198121040-00001